Alto Neuroscience, Inc. (ANRO)
- Sector
- Pharmaceuticals
- Last price
- $23.33
- As of
Kresmion compiles this page from ANRO's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Alto Neuroscience, Inc. (ANRO): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-27.
See the full ANRO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ANRO on one page. Preview it with sample data, then open it live with a free account.
Preview the ANRO dossierActive events for ANRO
- mediumEarnings above estimates
Q2-2026: Beat consensus by 13.2%, EPS $-0.65 vs $-0.7492 estimate
- mediumEarnings below estimates
Q1-2026: Missed consensus by 46.2%, EPS $-0.80 vs $-0.5473 estimate
FREE, NO ACCOUNT
Every event on ANRO, as it fires
New filings, 13F moves and cross asset events on ANRO land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ANRO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 02157Q109 · 2026Q2 | $14.7M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP 02157Q109 · 2026Q2 | $13.3M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 02157Q109 · 2026Q2 | $3.9M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 02157Q109 · 2026Q2 | $1.9M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ANRO
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ANRO against its peers
ANRO's return on equity of -41.8% ranks in the 28th percentile of 22 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | ANRO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 411M | n/a | 21 |
| Gross margin | n/a | 74.0% | n/a | 10 |
| Operating margin | n/a | 5.6% | n/a | 18 |
| Net margin | n/a | 0.2% | n/a | 19 |
| Return on equity | -41.8% | -14.3% | 28 | 22 |
| P / E | n/a | 15.6x | n/a | 9 |
Peers (25): ALMS, ESPR.D, AMPH, COLL, OMER, NKTR, PCRX, INVA, GPCR, PAHC, OCUL, NUVB, ANIP, ACRS, TRVI, XERS, HRMY, SUPN, BHC, AVIR, FULC, TARS, AMLX, BIOA, OGN. Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (ANRO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ANRO on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ANRO for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.